Not available
Quote | Leap Therapeutics Inc. (NASDAQ:LPTX)
Last: | $3 |
---|---|
Change Percent: | 1.34% |
Open: | $2.94 |
Close: | $3 |
High: | $3.135 |
Low: | $2.9245 |
Volume: | 146,417 |
Last Trade Date Time: | 04/17/2024 03:00:00 am |
News | Leap Therapeutics Inc. (NASDAQ:LPTX)
2024-04-12 11:34:12 ET More on S&P 500 Index: Sticking With The More Optimistic View Where We Stand Sorry Campers, The Fed Is Not Riding To The Rescue Nasdaq, S&P, Dow slip as major banks kick off earnings season Nasdaq, S&P climb, Dow end...
2024-04-11 09:09:06 ET More on Leap Therapeutics Seeking Alpha’s Quant Rating on Leap Therapeutics Historical earnings data for Leap Therapeutics Financial information for Leap Therapeutics Read the full article on Seeking Alpha For further det...
Message Board Posts | Leap Therapeutics Inc. (NASDAQ:LPTX)
Subject | By | Source | When |
---|---|---|---|
No one in their right mind gives 2 | VivaLasVegas | investorshub | 05/27/2022 4:28:22 AM |
LPTX Piper ups Leap Therapeutics target to $6 | stockguard | investorshub | 01/24/2022 12:19:32 AM |
AviseAnalytics: 4 SMALL-CAP BIOTECH STOCKS FOR YOUR INVESTMENT PORTFOLIO! $LPTX $VYGR $OCUL $MNMD | AviseAnalytics | investorshangout | 11/01/2021 12:06:18 PM |
yep, something big happening here. | Deano361 | investorshub | 09/30/2021 7:24:17 PM |
4.08 > hod. | crudeoil24 | investorshub | 09/30/2021 6:33:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy ...